Loading clinical trials...
Loading clinical trials...
A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared With Placebo or Standard of Care for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Conditions
Interventions
SPR720
Placebo
+1 more
Locations
9
United States
Medical Facility
Altamonte Springs, Florida, United States
Medical Facility
Atlantis, Florida, United States
Medical Facility
Clearwater, Florida, United States
Medical Facility
Kissimmee, Florida, United States
Medical Facility
West Palm Beach, Florida, United States
Medical Facility
Charlotte, North Carolina, United States
Start Date
December 3, 2020
Primary Completion Date
January 28, 2021
Completion Date
January 28, 2021
Last Updated
February 28, 2022
NCT05824988
NCT00599079
NCT00598962
Lead Sponsor
Spero Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions